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Introduction: Endometrial hyperplasia has a high risk for malignant transformation and relapses; existing
mini-invasive treatments may lead to irrevocable endometrium destruction. The aims were to analyze receptor
systems in endometrial hyperplasia, to evaluate the capabilities of ultrasonography, sonoelastography for diagnosis
and treatment control, and to develop treatment algorithm.
Materials and methods: We included 313 women (20–45 years), assessed into the following: group 1 (n = 112) with
glandular cystic hyperplasia, group 2 (n = 98) endometrial polyps, and group 3 (n = 103) atypical hyperplasia; and 82
controls who have undergone hysteroscopy before in vitro fertilization in tubal origin infertility were also included.
Patients underwent clinical examination, transvaginal ultrasound, immunohistochemical study, and hormonal
therapy/hysteroresectoscopy.
Results: In patients with glandular hyperplasia, we registered increase of endometrium estrogen receptors (75.6%
in the epithelium and 30.9% in the stroma; in controls, 43.3% and 29.6%, respectively); in polyps, there was a
significant estrogen receptor increase in the stroma (48.2% vs 29.6% in controls), and in atypical hyperplasia,
progesterone receptors significantly increased in the stroma. Ki-67 increased (40% to 50%) in the epithelium without
changes in the stroma. Ultrasound has a sensitivity of 96% and a specificity of 85% for early detection of endometrial
pathology and prediction outcome of intervention, and sonoelastography has a sensitivity of 91% and a specificity of
83% for polyp diagnosis. Personalized treatment was effective in 88.8%, relapse was diagnosed in 11.2% after 6 months,
and conservative treatment of atypical hyperplasia was effective in 45%: in 25.8%, ablative hysteroresectoscopy
was performed, while in 22.6% with comorbidities, hystero/oophorectomies were performed.
Conclusions: The evaluation of receptor status with ultrasound data in patients with endometrial hyperplasia
allows for a clear definition of the treatment policy, avoidance of relapse, treatment optimization, and observation
of such patients.
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Current evidence for predictive, preventive, and
personalized strategy for endometrial hyperplasia
Women's health and gender-related pathology remain
the priorities for predictive, preventive, and personalized
medicine (PPPM) [1,2]. Relevance of endometrial hyper-
plasia (EH) study is primarily due to a high risk for
malignant transformation and the problems associated
with menstrual irregularities, dysfunctional uterine bleed-
ing, and anemia in women. Endometrial hyperplasia has
a significant place in the structure of gynecological mor-
bidity in women of reproductive age and is one of the
most frequent causes of hospitalization in gynecology
hospital (10% to 18%) [3].
Endometrial hyperplasia may cause endometrial cancer
in up to 50% of cases [4]. The incidence of endometrial
adenocarcinoma, which ranks first among genital malig-
nancies, not only has remained high but in recent years
has tended to significantly increase in many countries,
including Ukraine, and according to long-term progno-
sis, it will not diminish anytime soon [3,5]. Endometrial
cancers are the most common gynecologic cancers in
developed countries [6]; therefore, careful search for
malignancy, particularly in women with multiple risk
factors, is advised by many researchers in daily practice
[6,7]. With the high rate of endometrial hyperplasia
recurrence, the risks of malignancy require further im-
provement and new approaches to diagnosis and treat
of this disease should be found [8]. Additional studies
on histological features and immunohistochemical profiles
are needed to find associations between endometrioid and
high-grade endometrial carcinoma and endometrial path-
ology. Differences in the immunohistochemical expression
of p53, B cell lymphoma 2 (Bcl-2), bax, estrogen receptor
(ER), and progesterone receptor (PR), androgen receptor
(AR), progesterone receptor antagonists (PA), etc. should
be properly assessed to find the most common diagnostic
pitfalls and helpful morphological and immunohisto-
chemical markers.
Endometrial hyperplasia in reproductive-aged women
The endometrium of reproductive-aged women under-
goes cyclic developmental changes in response to the
steroids - estrogen and progesterone.
The highest score of ERs and PRs is observed in the
epithelial and stromal cells of the normal endometrial
uterine at the early proliferative phase; then, throughout
the secretory phase, the ER and PR scores decline. In
typical endometriotic lesions, the ER and PR scores are
constantly high, but they are independent of the men-
strual cycle. The expression pattern of ER mRNA is re-
ported mostly in parallel with that of ERs. In typical
endometriosis, ERs and PRs are found in both glandular
epithelial cells and in their surrounding stromal cells.Expression of ER mRNA was found in typical endometrio-
tic peritonea and in the pelvic peritoneum with columnar
epithelial cells, but not in the normal pelvic peritoneum
(mesothelium). Estrogen receptors and PRs were found
negative in the mesothelium but were positive in the
nuclei of fibroblasts in the connective tissue [9].
Gregory et al. postulated that an increased in the coacti-
vator expression may render the endometrium to be more
sensitive to estrogen [10]. Specific coactivator expression
patterns were found in the fertile endometrium and in
anovulatory (proliferative) and clomiphene-induced ovula-
tory (secretory) women with polycystic ovarian syndrome
(PCOS), who have a higher likelihood of developing
estrogen-induced endometrial hyperplasia and cancer.
Women with PCOS exhibited elevated levels of ampli-
fied in breast cancer-1 (AIB1) and transcriptional inter-
mediary factor-2 expression in both the epithelial and
stromal cells [10]. Their receptors are regulated by ster-
oid receptor coactivators of the p160 family, namely
steroid receptor coactivator-1, AIB1, and transcriptional
intermediary factor-2, in the human endometrium ob-
tained prospectively from normal fertile women through-
out the menstrual cycle. Glandular AIB1 increases in the
late secretory phase [10]. The authors described an in-
creased expression of ERα (an estrogen-induced gene
product) during the menstrual cycle in the PCOS endo-
metrium and overexpression of p160 in the endomet-
rium of women with PCOS. These data explain the poor
reproductive performance observed in PCOS and the
increased incidence of endometrial hyperplasia and can-
cer noted in this group of women.
The effects of estradiol (E), progesterone (P), and PA
were studied on the endometrium of rhesus macaque
[11]. Ovariectomized macaques were treated with im-
plants of E and P to induce precisely controlled, artificial
menstrual cycles. During these cycles, treatment with E
alone induces an artificial endometrial epithelial cell pro-
liferation and increased expression of stromal and epithe-
lial ER and PR. Androgen receptor E in the endometrial
stroma is also upregulated. Progesterone acts on the
E-primed endometrium to induce secretory differenti-
ation and causes suppression of epithelial and stromal
ER, epithelial PR, and stromal AR in the functionalis
zone. However, epithelial ER and PR are retained in the
basalis zone during the secretory phase. When potent PA
are administered acutely at the end of an E(2) + P-induced
cycle, menses typically ensues similarly to P withdrawal
at the end of the menstrual cycle. When PAs are admin-
istered chronically, there is significant blockage of all
P-dependent effects including upregulation of ER, PR,
and AR and suppression of glandular secretory function.
However, chronic PA administration also inhibits estrogen-
dependent endometrial cell proliferation and growth. This
experimental data endometrial anti-proliferative effect is
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eases such as endometriosis [11].
Atypical endometrial hyperplasia
Atypical endometrial hyperplasia (AEH) has the highest
cancer threat; the prevalence of endometrial carcinoma
in patients who had a community hospital biopsy diag-
nosis of AEH was high (42.6%). When considering man-
agement strategies for women who have a biopsy diagnosis
of AEH, clinicians and patients should take into account
the considerable rate of concurrent carcinoma [12]. Malig-
nant tumors after AEH diagnosis demonstrate features of
good prognosis with endometrioid morphology, lower
grade, and early stage, although the overall positive pre-
dictive value of AEH is expected at 37% to 48% in the
current routine practice [13].
Endometrial cancer
Endometrial cancer is frequently seen in women with
post-menopausal bleeding and endometrial hypertrophy
in ultrasound examination, especially when the endo-
metrial image is non-homogenous and irregular. How-
ever, the rarest endometrial cancers were affirmed in
post-menopausal women with the ultrasound image of
fluid in the uterine cavity with thin endometrium [14].
Endometrial cancers are classified into types I and II
based on light microscopic appearance, clinical behavior,
and epidemiology. This classification of endometrial can-
cers considers genetic analysis, and histologic subtypes
are underscored by systematic changes in a limited set
of genes. Common genetic changes in endometrioid
endometrial cancers include, but are not limited to,
microsatellite instability or specific mutation of PTEN,
K-ras,12,22-28, and β-catenin genes [15].
Type I comprises 70% to 80% of newly diagnosed cases
of endometrial cancer, is associated with unopposed
estrogen exposure, and is often preceded by a pre-
malignant disease.
Type II of endometrial cancers has a non-endometrioid
histology (usually papillary serous or clear cell) with an
aggressive clinical course. Hormonal risk factors have
not been identified, and there is no readily observed
pre-malignant phase. Combined molecular, histomor-
phometric, and clinical outcome analysis of premalig-
nant lesions has provided a clearer multidisciplinary
definition of endometrial pre-cancers, known as EIN.
Genetic and endocrine disease mechanisms have been
integrated into a multistep model for oncogenesis in
which hormonal exposures act as selection factors for
mutated endometrial cells [15].
The findings of Kounelis et al. [16] indicate the differ-
ences in immunohistochemical profiles of endometrioid
and serous carcinomas. Thus, uterine papillary serous
adenocarcinomas (UPSA) show a significantly higherp53 expression than uterine endometrioid adenocarcin-
omas; there is no significant difference in Bcl-2 and bax
expression between both histologic types. Overexpres-
sion of p53 is associated with high-grade endometrioid
carcinoma and advanced-stage tumors, while ER and PR
expressions were associated with low-grade and early-
stage tumors. Bcl-2 immunopositivity is more common
in low-grade, early-stage adenocarcinomas rather than
in high-grade, advanced-stage adenocarcinomas, but the
difference was not statistically significant. Bax immuno-
positivity is associated with well-differentiated and early-
stage tumors. There was a significant inverse relationship
between bax and p53 reactivity, especially in tumors of
endometrioid type [16,17]. Early detection of p53 nuclear
accumulation may help to identify precursor lesions of
UPSA. Bcl-2 persistence is frequently associated with
endometrial carcinoma, and failure to inactivate Bcl-2
expression probably is related to the development of
endometrial carcinoma [17].
The presence of testosterone receptors in estrogen
receptor-positive endometrial carcinomas may be involved
in the mechanism of cell proliferation in these tumors.
The strong staining reaction for testosterone receptors
in the endometrial glands can be considered one of the
features of invasive malignancy [18].
Bartoschet et al. [19] suggest differential diagnosis be-
tween the different subtypes of endometrial carcinomas
including (1) endometrioid versus serous glandular car-
cinoma, (2) papillary endometrioid (not otherwise speci-
fied, villoglandular and non-villous variants) versus serous
carcinoma, (3) endometrioid carcinoma with spindle cells,
hyalinization, and heterologous components versus malig-
nant mixed Müllerian tumor, (4) high-grade endometrioid
versus serous carcinoma, (5) high-grade endometrioid
carcinoma versus dedifferentiated or undifferentiated
carcinoma, (6) endometrioid carcinoma with clear cells
versus clear cell carcinoma, (7) clear cell versus serous
carcinoma, (8) undifferentiated versus neuroendocrine
carcinoma, (9) carcinoma of mixed cell types versus car-
cinoma with ambiguous features or variant morphology,
(10) Lynch syndrome-related endometrial carcinomas,
and (11) high-grade or undifferentiated carcinoma versus
non-epithelial uterine tumors. As carcinomas in the endo-
metrium are not always primary, this becomes the dif-
ferential diagnosis between endometrial carcinomas and
other gynecological, as well as with extra-gynecologic
metastases.
Breast cancer patients receiving tamoxifen (Tam) are
at an increased risk for developing endometrial carcin-
omas, possibly due to the partial estrogenic effect of Tam
on endometrial cells. Progestational therapy has not rou-
tinely been included in Tam regimens. The consistent
finding of ER and PR expression in the endometria of
post-menopausal women receiving Tam further supports
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metrial cells. Progestational therapy could be beneficial in
the prevention of Tam-induced abnormal endometrial
proliferations [20].
Mutter et al. showed that 43% of histologically normal
pre-menopausal endometria contain rare glands that fail
to express the PTEN tumor suppressor gene because of
mutation and/or deletion. This persists between menstrual
cycles. Histopathology of PTEN-null glands is initially
unremarkable, but with progression, they form distinct-
ive high-density clusters. These data are consistent with
a progression model in which initial mutation is not rate
limiting [21].
A physiologic process of apoptosis involved in the cyclic
growth of normal endometrium [22,23] can be induced by
extrinsic factors such as chemotherapeutic drugs and radi-
ation [24]; the oncoprotein Bcl-2 is a well-known regula-
tor of cellular apoptosis, inhibiting physiologic process
[25]. Progestin-induced apoptosis may occur during the
early period of treatment for endometrial hyperplasia [26].
Fas-Fas binding plays a fundamental role in the regulation
of the immune system, triggers apoptosis, and may be in-
volved in the development of endometrial hyperplasia
[27]. Bax/Bcl-x may be the major control mechanisms
of apoptosis in advanced carcinomas; other members of
the Bcl-2 family may also be under hormonal control [28].
Fas-related apoptotic pathway is also involved in the
regulation of apoptosis in the endometrial tissue and
promotes the development and progression of endomet-
rial neoplasia, considering a significant increase of Fas,
caspase-3, and M30 expressions in carcinomas [29].
Transition of endometrial epithelium from hyperplasia
to cancer seems to involve both increased apoptosis and
decreased Bcl-2 expression. Flow cytometric evaluation
of M30 and Bcl-2 expression levels, with SPF, in curettage
specimens from post-menopausal patients complaining of
bleeding provides a quantitative assessment of endomet-
rial apoptosis, anti-apoptosis, and proliferation. Further
studies are needed to determine the relationship among
these three processes as indicators of the biological behav-
ior of gynecological tumors [30].
Evidence for the existence of adult stem/progenitor
cells in human and mouse endometrium is now emer-
ging because functional stem cell assays are being ap-
plied to uterine cells and tissues [31].Polyps
Polyps from the endometrium cause abnormal uterine
bleeding, infertility, and pelvic pain [32]. Endometrial
polyps undergo cyclic changes in the expression of their
proteins related to proliferation and apoptosis during
the menstrual cycle, similar to those of the cycling endo-
metrium [33].The concentrations of ER and PR in the glandular epi-
thelium were significantly higher in endometrial polyp
than in the normal endometrium. The concentrations of
these receptors in the glandular epithelium and stroma
were similar in the post-menopausal and pre-menopausal
patients [34].
Mittal et al. concluded that endometrial polyps may be
a result of a decrease in ER and PR expression in stro-
mal cells. Because of these receptor-negative stromal
cells, endometrial polyps may relatively be insensitive to
cyclic hormonal changes [32]; while the concentrations
of ER and PR in glandular epithelium were higher in
polyps than in the normal endometrium, the concentra-
tions of these receptors in the glandular epithelium and
stroma are similar in the post-menopausal and pre-
menopausal patients. The study by Peng [35] that mea-
sured the expression of hormone receptors (estrogen
receptor and progesterone receptor) in endometrial
polyps and compared the results to surrounding endo-
metrial tissue in women prior to menopause showed
that the expression of estrogen receptor was higher
whereas the expression of progesterone receptor was
lower than that of the adjacent endometrial tissue. The
results suggest that the abnormal expression of hormone
receptor contributes to endometrial polyp formation.
Fujishita et al. demonstrated the expression of ERs, ER
mRNA, and PRs in the columnar cells of the pelvic peri-
tonea and typical endometriosis, but not in the normal
mesothelium. These results suggest that endometriosis
may originate from the columnar cells with ERs and
PRs in the pelvic peritoneal lining [9].
Endometrial polyps can appear in menopausal women
receiving hormone replacement therapy despite the
presence of progestins to oppose the action of estrogens
[36]. Hormone replacement therapy (HRT) impacts on
the expression of Ki-67, Bcl-2, and c-erb.B2 in endomet-
rial polyps during menopause and may cause endomet-
rial polyp involution by decreasing proliferation and
stimulating apoptosis [37].
Vereide AB showed that proteins in the apoptotic cas-
cade are regulated by gestagen; stromal Bcl-2 expression
is a potential biomarker which can separate responders
of gestagen treatment from non-responders after oral
administration [38]. Part of the molecular mechanisms
of progestin therapy for endometrial hyperplasia is through
the upregulation of Fas/FasL expression [27]. Dysregulation
of Fas/FasL expression in hyperplastic endometrium may
be part of the molecular mechanisms for non-responders
to progestin treatment. Intermittent, rather than continu-
ous, progestin treatment may be more effective clinically
for the treatment of endometrial hyperplasia.
Taylor et al. [39] demonstrated three significant differ-
ences found between the endometrium and the polyps.
Polyps taken from the proliferative phase of the cycle
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a weak or no expression of progesterone receptors.
Secretory phase polyps displayed an elevated expression
of estrogen receptors.
A localized increase in Bcl-2 expression and conse-
quential decline or cessation of apoptosis are important
mechanisms underlying the pathogenesis of endometrial
polyps. Elevated Bcl-2 expression results in failure of the
polyp tissue from undergoing normal cyclical apoptosis
during the late secretory phase [39-41]. This may mean
that the polyp is not shed along with the rest of the
endometrium during menstruation.
However, estrogen may have a role in the development
of post-menopausal endometrial polyps, either by direct
stimulation of localized proliferation or by stimulation of
proliferation via other pathways, such as activation of
Ki67 or through inhibition of apoptosis via Bcl-2. The
c-erbB-2 is unlikely to play any role in the development
of these lesions [42]. Ki-67 and c-erbB2 overexpressions
are frequent in endometrial polyps in post-menopausal
women [43].
Endometrial polyps in menopausal patients receiving
HRT respond only to estrogens, but not to progestins.
The unopposed estrogenic action on polyps may favor
the development of pre-malignant hyperplasia and car-
cinoma [44].Ultrasound
Ultrasound diagnosis has been successfully used to dif-
ferentiate tumors of the uterus and appendages [45-52].
Transvaginal ultrasound is a cost-minimizing screening
tool for perimenopausal and post-menopausal women
with vaginal bleeding [45] and is preferred over uniform
biopsy of post-menopausal women with vaginal bleeding
because it (1) is a less invasive procedure, (2) is generally
painless, (3) has no complications, and (4) may be more
sensitive for detecting carcinoma than blind biopsy. Trans-
vaginal sonography is rarely non-diagnostic. A limitation of
ultrasound is that an abnormal finding is not specific: ultra-
sound cannot always reliably distinguish between benign
proliferation, hyperplasia, polyps, and cancer; that should
not be seen as a crucial limitation because tissue sampling
is required in either case. Ultrasonography also may be
used as a first-line investigation in other populations
with abnormal uterine bleeding. In a multicenter, ran-
domized, controlled trial of 400 women with abnormal
uterine bleeding by Davidson and Dubinsky [45], the in-
vestigators found that transvaginal sonography combined
with Pipelle endometrial biopsy and outpatient hysteros-
copy was as effective as inpatient hysteroscopy and curet-
tage [45]. Occasionally (in 5% to 10% of cases), a woman's
endometrium cannot be identified on ultrasound, and
these women also need further evaluation.Transvaginal ultrasonography has a poor positive pre-
dictive value but has a high negative predictive value for
detecting serious endometrial diseases in asymptomatic
post-menopausal women [46]. A limit of M-echo thick-
ness at 8 mm [47] or 10 mm [48] was suggested for this
category of patients, as the upper limit for normal thick-
ness was also suggested on a value of 9 mm in women
receiving treatments associated with thicker endometria
(estrogen alone and cyclical combinations) [49-51].
The negative predictive value for ultrasonography was
high (99%) when the threshold for endometrial thickness
was 5 mm. This high negative predictive value is not a
justification for the use of ultrasonography in screening
since 53% of the women with normal biopsies were
reported to have an endometrial thickness of at least
5 mm [46].
Nordic multicenter study showed that the risk of
finding pathologic endometrium at curettage when the
endometrium is <4 mm as measured by transvaginal
ultrasonography is 5.5%. Thus, in women with post-
menopausal bleeding and an endometrium <4 mm, it
would seem justified to refrain from curettage [52].
According to Fleischer et al., the sampling rate of women
with an endometrial thickness >6 mm was too low (45%)
for confidence interval in the positive predictive value
of 2%. Despite a high negative predictive value (99%),
transvaginal ultrasonography may not be an effective
screening procedure for the detection of endometrial
abnormality in untreated post-menopausal women who
are without symptoms [53].
Ultrasound imaging of endometrium with atypical
hyperplasia in post-menopausal women was found non-
homogenous and irregular, and the rarest was in the
cases of affirmed fluid in uterine cavity [14].
According to statements of the Consensus of Society
of Radiologists [54], the following recommendations were
used to create an algorithm for evaluating women with
post-menopausal bleeding:
 Because post-menopausal bleeding is the most
common presenting symptom of endometrial cancer,
when post-menopausal bleeding occurs, clinical
evaluation is indicated;
 Either transvaginal sonography or endometrial
biopsy could be used safely and effectively as the
first diagnostic step. Whether sonography or
endometrial biopsy is used initially depends on the
physician's assessment of patient risk, the nature of
the physician's practice, the availability of high-
quality sonography, and patient preference. Similar
sensitivities for detecting endometrial carcinoma are
reported for transvaginal sonography, when an
endometrial thickness >5 mm is considered abnormal,
and for endometrial biopsy, when ‘sufficient’ tissue is
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morbidity, and quality-of-life end points, there are
insufficient data to comment as to which approach
is more effective [55-57].
A combination of transvaginal sonography, Pipelle
endometrial biopsy, and outpatient hysteroscopy (1) has
similar efficacy to inpatient hysteroscopy and curettage
for the investigation of abnormal uterine bleeding;
(2) hysteroscopy will detect some fibroids and polyps
missed by a combination of transvaginal ultrasound
and Pipelle endometrial sampling; (3) the quality of
histological samples obtained by outpatient Pipelle were
comparable to those obtained by formal inpatient curet-
tage; and (4) outpatient procedures were well tolerated,
with good patient acceptability [58].
Sonoelastography
Today, a new non-invasive method of examination,
sonoelastography (SEG), which is based on the ultra-
sonic examination of tissues softness, is constantly de-
veloping. SEG as a tissue strain imaging was first described
in 1991 [59]. The phenomenon is based on the fact on
inverse scattering ultrasonic signal in mild compression
and relaxed (i.e. approximately 2%) insonated tissue
during the study. The main advantage of such a diagno-
sis is its high sensitivity. However, there is still a lack of
evidence regarding endometrial assessment using SEG.
Thus, Preis et al. [60] in a group of 35 perimenopausal
patients obtained a sensitivity value of sonoelastography
for endometrium hyperplasia as high as 100%. However,
the bigger group of patients has to be analyzed to con-
firm specificity and accuracy. Recently, we suggested the
use of blue-green-red (BGR) sonoelastography artefact
as a sign to indicate the presence of fluid content in cav-
ities for predicting the liquid content and the possibility
for puncture. Ovarian cyst sonoelastography can be
effective for liquid detection and has an 88% positive
predictive value [61].
Treatment
Taking into account the fact that the sensitivity to hor-
mone therapy and prognosis of EH in women is largely
determined by receptor status, which depends on the
clinical stage and degree of histological differentiation of
endometria, the aim of our study was to determine the
characteristics of endometrial receptors using immuno-
histochemical methods [3,8].
On the other hand, we are aware of a percentage of
patients whose progestin treatment does not give the
desired results; we believe that it is this category of
patients that is subject to special individual approach
to treatment and observation. After hormonal treatment,
EH relapses occurred in 15%, 9% to 27%, and 2% ofpatients due to the morphological heterogeneity of endo-
metrial proliferation. The sensitivity to therapy and prog-
nosis are largely determined by the receptor status.
Existing methods such as cryosurgery, laser destruction
and electrodestruction, and thermoablation may lead to
irrevocable destruction of the endometrium. The prac-
tice of minimally invasive ablation made possible the
removal of the endometrium basal layer.
Hysteroresection of the endometrium is considered to
be the most reliable technique for the management of
endometrial pathology and uterine bleeding because it
provides information on the histologic characteristics of
endometrium, removal of the tissue within a prescribed
depth, and coagulation of bleeding sites.
Hysteroscopy is likely to become the new gold stand-
ard in the future because of its ability to visualize dir-
ectly the endometrium and perform directed biopsies as
indicated. As office-based hysteroscopy becomes more
practical and widespread, the technique may become more
cost effective. An evaluation plan using transvaginal sonog-
raphy as the initial screening evaluation followed by endo-
metrial biopsy or, more likely, hysteroscopy is likely to
become the standard of care.
In recent years, with the introduction of new endoscopic
technology, the range of surgical treatment methods for
this category of patients has expanded, particularly for
those patients with concomitant somatic pathology. One
of these innovative treatments is endometrial ablation,
the essence of which is the hysteroscopic removal of the
basal layer in order to achieve amenorrhea [3]. Reliable
visual control ensures efficiency of minimally invasive
technologies in all spheres of gynecologic practices.
It remains unproven whether certain patients at higher
risk for carcinoma should proceed directly to invasive
evaluation. Patients on tamoxifen with persistent recur-
rent bleeding, those with significant risk factors for car-
cinoma, and patients with life-threatening hemorrhage
comprise this group. Further studies are still necessary
to evaluate high-risk patients and determine whether
ultrasound or biopsy is really the most cost-effective ini-
tial test [45].
These facts confirm the need to determine a new inte-
grative view assessing the state of receptor systems and
sonography data for each case, to reach a personalized
treatment strategy.
The aims of this strategy were as follows:
 to assess the state of receptor systems in
endometrial hyperplasia,
 to evaluate the capabilities of ultrasound diagnostics
and sonoelastography for diagnosis of endometrial
pathology and control minimally invasive treatment,
 to develop algorithm for personalized treatment for
patients with endometrial hyperplasia with regard to
Table 1 Immunohistochemistry markers
Marker Clone Catalogue number
Estrogen receptor (SP1) SP1 RM-9101-S
Progesterone receptor (SP2) SP2 RM-9102-S
Ki-67 (SP6) SP6 RM-9106-S
p53 Y5 RM-2103-S
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and radiology biomarkers.
Methods
We included in the study 313 white Ukrainian women
aged 25 to 45 years who were treated at the Gynecology
Center of the Clinical Hospital ‘Pheophania’ from January
2010 to June 2013; they were divided into the following:
group 1 (n = 112) with glandular cystic hyperplasia, group
2 (n = 98) with endometrial polyps, and group 3 (n = 103)
with atypical endometrial hyperplasia; 82 women who
underwent hysteroscopic investigation for infertility before
the cycles of in vitro fertilization were included as the
control group. Age of women included in the observa-
tion group ranged from 20 to 45 years, and the average
was 38.0 ± 2.3 years.
Diagnosis of EH was combined with dysfunctional
uterine bleeding (82.3%), inflammatory diseases of geni-
tals (77.4%), and endocrine diseases, such as obesity, thy-
roid disease, and diabetes (35.5%), which, together with
sensitivity of maintaining reproductive to hormone ther-
apy functions, were considered for personalized treat-
ment. The patients were distributed into the groups with
non-significant difference among groups as regards to
age. The design of the study was prospective and non-
randomized.
All patients underwent general clinical examination,
which included clinical and biochemical blood tests;
blood tests for HIV, RW, HBS-Ag, and HCV-Ag; clinical
urine tests; ECG; ultrasound; chest X-rays; and a study
of vaginal biotope (microflora), according to protocols of
the Ministry of Health of Ukraine. In the study group,
diagnostic search was conducted using ultrasound to
maintain hysteroresection. The resulting material was
subjected to a histological study to determine the recep-
tor of the endometrium cells applying immunohisto-
chemical method, depending on the outcome of patients
who later designed the appropriate medical tactics.
Ultrasonography
All patients underwent clinical examination, transvaginal
ultrasound (US) scanning including sonoelastography
and 3D/4D technology. Months (1, 3, 6, and 12) after
hysteroresectoscopy, we evaluated the endometrial struc-
ture, thickness, margins, with myometrium within the
TV US diagnostic protocol. Ultrasound scanning using
transvaginal probes of the ultrasound scanner HITACHI
7500 (Tokyo, Japan) with a frequency of 5–8 MHz was
carried out before, immediately after, and 1and 6 months
after the intervention. To define the sonoelastography
patterns and the comparative analysis, we used a visual
grading system (grades 1–5), which was adopted accord-
ing to the color variation. The color scheme was red
(soft), green (medium stiffness), and blue (hard). Three-dimensional US imaging was performed on Siemens
Elegra (Munich, Germany). The uterus was scanned in
the coronal and longitudinal projections. The thickest
anteroposterior diameter of the endometrial stripe was
measured in the sagittal plane.
Hysteroresection
Hysteroresectoscopies were performed using an 8-mm
unipolar resectoscope (Karl Storz GmbH & Co., KG,
Tuttlingen, Germany). After 6 months, we performed a
control hysteroscopy with endometrial biopsy to assess
therapy effectiveness.
On the first stage, the nature of the pathological
process in the endometrium was determined by con-
ducting diagnostic hysteroscopy with mandatory scrap-
ing of the walls of the uterus with pathohistological
verification of the diagnosis. On the second phase, hys-
teroscopic endometrial ablation was carried out with
subsequent follow-up. During the year, we performed
ultrasonography of the endometrium on the control with
the definition of the M-echo (at 1, 3, 6, and 12 months
after hysteroresectoscopy), which clarified the nature of
the menstrual function. Written informed consent was
obtained from all patients for the publication of this
report and any accompanying images.
Pathology
Endometrial biopsies were performed mainly in the late
proliferative stage phase. Sections were stained with
hematoxylin and eosin. Estrogen receptor (SP1), proges-
terone receptor (SP2), Ki67, and p53 were measured on
paraffin sections using the manufacturer's recommended
protocol (Thermo Scientific, Waltham, MA, USA), as
presented in Table 1. For evaluation of reactions, we
used a point scale assessment developed by the manu-
facturer, and immunohistochemical reaction to receptors
counted positive in the presence of at least three points.
As a de-masking maneuvre, we heated glasses on a
steam bath. For immunohistochemistry reaction, we used
rabbit monoclonal antibodies. To visualize the results
of immunohistochemical reaction, we used the peroxid-
ase of universal set, UltraVision LP Detection System:
HARP Polymer (RUT). Background fabric painting was
provided with hematoxylin.
The medical ethics commissions of the Clinical Hospital
‘Pheophania’ of State Affairs Department approved the
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parison between groups.Results
Analysis of the work found that glandular cystic hyper-
plasia of the endometrium occurs during anovulatory cy-
cles which tend to be longer than the normal menstrual
cycle after prolonged persistence of follicles, most of
which frequently occur in women 40–45 years who are
bleeding prior to amenorrhea for 1 and 2–5 months.
The extended phase of anovulatory cycles results from
prolonged high concentration of estrogen, resulting in
endometrial hyperplasia which is processed as glandular
(non-atypical complex hyperplasia) or glandular cystic
(simple non-atypical hyperplasia) endometrial hyperpla-
sia. A hysteroscopic image of glandular cystic hyperpla-
sia is shown in Figure 1.
In the histological examination, no distribution on the
compact and spongy layers was revealed and glands were
unevenly distributed in the stroma; the second type was
characterized by cystic expanded glands. Thus, in con-
trast to atypical hyperplasia, the number of glands did
not increase, but due to proliferation of the glandular
epithelium, each tube was lengthened and had a winding
form. Therefore, the histological sections are determined
as if the number of glands increased. There are three
options for hormonal endometrial proliferation: it could
proliferate in the most frequently occurring patterns,
characterized by an equal proliferation of glands and
stroma (65%); the structure could have a predominance
of stromal proliferation (25%); and the structure could
be dominated by the proliferation of glands (10%).
The content of estradiol and progesterone receptors
in epithelial cells and stroma with glandular cysticFigure 1 Hysteroscopic image of glandular cystic hyperplasia
of the endometrium.hyperplasia of the endometrium with immunohisto-
chemical study is presented in Figure 2.
In patients with glandular cystic hyperplasia, the con-
centration of estradiol receptors in epithelial cells was
significantly higher as compared to that in the control
group. Thus, the content of estradiol receptors in epithe-
lial cells was 75.6%, while the rate in the control group
was 43.3% (Figure 3).
Our findings did not show significant changes in stro-
mal content in these groups (30.9% in the group with
glandular hyperplasia and 29.6% in the control group).
In our opinion, this is due to the type of hyperplasia.
Glandular cystic hyperplasia is usually characterized by
irregular proliferation of glandular and stromal compo-
nents due to irregular activation of the receptor system
of glands and stroma; the number of progesterone re-
ceptors in epithelial cells and stroma in patients with
glandular cystic hyperplasia was slightly higher than in
the control group (69.3% in the epithelial cells and
62.2% in the stroma in patients with glandular cystic
hyperplasia; 52.4% and 48.5% in the control group,
respectively). This fact confirms the role and relative
hyperestrogenemia and hypoprogesteronemia at the cellu-
lar level for the proliferative state of the endometrium.
As the results of our research, the hormone levels do
not always determine the degree of proliferation; a sig-
nificant role in the pathogenesis of endometrial hyper-
plasia has a certain value of steroid hormone receptors
that causes the sensitivity of endometrial cells.
Immunohistochemical reaction in the endometrium
with glandular cystic hyperplasia of antibodies with es-
trogen and progesterone is shown in Figures 4 and 5.
While assessing receptor status in the immunohisto-
chemical study, we also determined the level of prolifer-
ative activity using the proliferative marker Ki-67. As
already was established, glandular cystic hyperplasia in
most cases was characterized by increased proliferationFigure 2 Glandular cystic hyperplasia. Coloring by
hematoxylin-eosin (×40).
Figure 3 Content of estradiol and progesterone receptors (%)
in the endometrium with glandular cystic hyperplasia.
Figure 5 Immunohistochemical reaction in the endometrium
with glandular cystic hyperplasia of antibodies with
progesterone (×40).
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eration. This was confirmed when the determining pro-
liferative marker expression was used in glandular cystic
hyperplasia. Thus, in functionally active glands, Ki-67
expression increases in some places up to 50% with an
almost negative reaction in glandular cystic hyperplasia.
Following this concept, we determined the distribution
of steroid receptors in patients with endometrial polyps
(Figure 6).
According to our findings, uterine polyp is a local le-
sion of exophytic growth, derived from the basal layer of
the endometrium. In the early stages of development,
polyps look like small proliferates located in the basal
section of the endometrium on the verge of the myome-
trium. Microscopically, these foci are different from the
surrounding normal endometrium disordered clusters of
tubular and glandular structures with low row indiffer-
ent epithelium type, surrounded by a dense cellular
stroma. The basal growth area of glandular proliferationFigure 4 Immunohistochemical reaction in the endometrium
with glandular cystic hyperplasia of antibodies with
estrogen (×40).
Figure 6 Hysteroscopy of intrauterine lesions. (A) Fibrous
endometrial polyp and (B) submucosal fibromyoma.
Figure 8 Hysteroscopic image of glandular endometrial polyp.
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them through expansive growth and bulges above the
surface as exophytic lesion. The surface of the polyp is
often covered with a layer of functional endometrium
that participates in the cyclic changes as the neighbour-
ing endometrium and is rejected in phase desquamation.
A hysteroscopic imaged of intrauterine lesions: endo-
metrial polyp and submucosal fibromyoma are shown in
Figure 6. Histology of one type of polyp, namely glandu-
lar cystic polyp, is shown in Figures 7 and 8.
In analyzing the immunohistochemical data of recep-
tor status in women with endometrial polyps, we found
a similar trend in the distribution of receptors in pa-
tients with glandular cystic hyperplasia.
Thus, in a group of polyps, we have identified some
differences: the number of estradiol receptors in the
stroma was significantly higher than those in the control
group; they were 48.2% and 29.6%, respectively. The
content of progesterone receptors in the stroma was
58.1% and 55.9% of endometrial epithelium, whereas in
the control group, the content of progesterone receptors
in the stroma was 48.5% and 52.4% in endometrial epi-
thelium (Figure 9).
According to conventional pathogenesis paradigms,
polyp is a hyperplastic process in the endometrium in re-
sponse to any stimulation (inflammation, hormonal imbal-
ances, etc.) that is not of tumor origin. The results of our
studies demonstrate that an imbalance of receptor status
is also relevant for the development of polyps, most not-
ably an imbalance of estrogen receptors in epithelial and
endometrial stroma. Immunohistochemical reaction in
the endometrium with polyps of antibodies with estrogen
and progesterone is shown in Figures 10 and 11.
Pathological proliferation of the endometrium, which
loses hormonal hyperplasia characteristics and has the
emergence of patterns inherent to malignant tumor, is
called atypical endometrial hyperplasia. According to
the degree of prevalence, diffuse and focal types are dis-
tinguished; according to the proliferation of glandularFigure 7 Glandular cystic endometrial polyp. Coloring by
hematoxylin-eosin (×40).and stromal components, simple and complex forms
are distinguished.
Histologically, we determined in atypical endometrial
hyperplasia the glands with numerous ramifications and
papillary projections that protruded into the lumen of
glands; they are strongly sinuous, with irregular shape.
Here and there, glands are closely located to each other
without stromal layers and are separated by a narrow strip
of connective tissue only. The epithelial cells of glands
acquired the features of tumor processes: reduction of
nuclear/cytoplasmic ratio, hyperchromatosis, nuclear
polymorphism, etc. There were proliferation and increased
mitotic activity and abnormal mitosis. Atypical endometrial
hyperplasia is shown in Figure 12.
The content of estradiol receptors in patients with atyp-
ical hyperplasia was significantly different from that of the
control group, as estradiol receptors in the epithelial cellsFigure 9 The content of estradiol and progesterone receptors
(%) in the endometrium with endometrial polyps.
Figure 10 Immunohistochemical reaction in the endometrium
with glandular cystic polyp of antibodies with estrogen (×40).
Figure 12 Atypical glandular hyperplasia of the endometrium.
Coloring by hematoxylin-eosin (×40).
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stroma, 42.6% (in the control, they were 43.3% and
29.6%, respectively; Figure 13).
There was a significant difference in the content of
progesterone receptors in the endometrial stroma (81.8%),
which was characterized by a sharp increase in what we
believe was a prognostic criterion for determining the
subsequent treatment strategy. Percentage of progester-
one receptors in epithelial cells was 44.3%, whereas in
the control, it was 52.4%. The increased concentration
of progesterone receptors in the stroma was probably
due to relative hypoprogesteronemia and thus was com-
pensatory anti-proliferative in nature.
However, this trend was not inherent for all observa-
tions; in 18.8% patients with atypical hyperplasia, we
determined low levels of estrogen receptors on the
decreased progesterone receptors' background.
Ultrasonography data
The study identified the most reliable ultrasound symptoms
of EH as follows: heterogeneity of the internal structure;
unclear, uneven outer contour; increasing thickness of
the M-echo and intensity of endometrial vascularization;
fluid in the uterine cavity; polypoid inclusions; and theFigure 11 Immunohistochemical reaction in the endometrium
with glandular cystic polyp of antibodies with estrogen (×40).registration of vascular signals in the subendometrial zone.
Ultrasound symptoms of EH are presented in Table 2.
Non-homogenous and irregular margins were signifi-
cantly higher in AEH than in both groups (P < 0.01). Mean
M-echo thickness was found to be non-significant. Hypoe-
choic areas, hypervascularity on Doppler imaging, and
stiffness (Figures 14 and 15) were more specific for AEH
than for glandular cystic hyperplasia (P < 0.01, P < 0.01,
P < 0.01, respectively; Figure 16). Fluid in the uterine
cavity and BGR artefact were found to be specific for
AEH (P < 0.01; Figure 17); BGR appearance correlated
to the presence of fluid in the uterine cavity (r > 0.97;
Figure 18).
Personalization of conservative treatment for AEH
With the main principle in determining the treatment
strategy for reproductive age patients which is maintain-
ing reproductive functions as sensitivity to hormoneFigure 13 The content of estradiol and progesterone receptors
in the endometrium with atypical endometrial hyperplasia.
Table 2 Ultrasound symptoms of endometrial hyperplasia
US symptom Glandular cystic hyperplasia Endometrial polyps Atypical endometrial hyperplasia
Non-homogenous and irregular margins 22% 27% 72%
Mean M-echo thickness 21 ± 2.1 mm 17 ± 1.8 mm 22 ± 2.2 mm
Hypoechoic areas 32% 44% 60%
Fluid in uterine cavity 25% 15% 38%
Hypervascularity on Doppler imaging 15% 42% 57%
RI 0.58 0.7 0.62
Prevalence
Stiffness (compared to myometrium) 45% 92% 65%
Isoelasticity (compared to myometrium) 35% 8% 27%
Softness (compared to myometrium) 30% - 7%
BGR 12% - 45%
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minimally invasive hysteroresectoscopy loop of 2 mm,
with subsequent progestin hormone therapy (endome-
trin), subsequent ultrasound, and histological control.
In women with endometrial abnormalities, scanty men-
struation was relatively rare (up to 3 days, 4.8%); menstrualFigure 14 Endometrial polyp (P). (A) Stiff polyps on SEG, arrow
indicates invisible polyp in grey scale that was detected on SEG;
(B) Dopplerography of polyp vessel, RI = 0.7.blood loss is in moderate intensity, lasting 4–6 days (8.0%),
is more common, and was found in 21.9% patients.
For patients with low expression of progesterone
receptor, we performed a personalized therapeutic strat-
egy considering age and comorbidities. In cases of in-
creased progestin receptors, we administered GnRH
agonists (Diferelin) for 6 months; it was followed by
recovery of menstrual function and purpose of proges-
tins (4.8% observations).
We found that in a group of reproductive-aged women,
conservative treatment was effective in 143 patients (45%),
and we have observed a normalization of menstrual func-
tion and ultrasound characteristics of the endometrium.
We considered a dynamic observation of ovary states for
conservative therapy (Figure 19).
In 82 patients (25.8%) older than 35 years, ablative sur-
gery was performed: hysteroresectoscopy to eliminate
atypical and basal layers in a single block. In 4.8% of
women, we observed EH relapse (polyposis) during pro-
gestin therapy, which required re-hysteroresectoscopy,
followed by appointment of GnRH agonists (Diferelin)Figure 15 Sonoelastography of endometrial lesion. Soft pattern
on SEG helps to exclude the polyp.
Figure 16 Glandular cystic hyperplasia that is softer than the
myometrium on SEG. E endometrium.
Figure 18 Polyp fluid in the uterine cavity. BGR artefact marks a
fluid in the uterine cavity in AEH. Sonoelastography appearance of
shades of color (blue, green, and red) through stratification artefact -
BGR - a sign indicating the presence of fluid in cavities.
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ion, the cause of EH recurrence was insufficient electro-
destruction due to the specific anatomy of the uterus
(Figure 20). In the 22.6% of patients with AEH and co-
morbidities (large uterine fibroids, ovarian cystadenoma),
hystero/oophorectomies were performed.
Quality of interventions needs the personalization of
minimally invasive treatment of endometrial pathology
Duration of surgery was 34.7 ± 9.3 min on average, while
duration of hospitalization was 3.5 ± 1.2 h. The end point
was the radical removal of diseased tissue; there was no
recurrence of pathological processes in the endometrium.
Our research has shown that the use of methods of hys-
teroscopic endometrial ablation in 88.8% of patients had
no endometrial dynamics by ultrasound, reducing the
size of the uterus in relation to the original. However,
the dynamic follow-up examination at 6 months was
found to be 11.2% in women; M-echo increased in thick-
ness, and there was vaginal bleeding from the genital tract,Figure 17 AEH endometrium (E) that is softer than the
myometrium on SEG. Fluid inclusions and BGR artefact (+) are
denoted by an arrow.which was the reason for the control of hysteroscopy in
order to clarify the state of the cavity cancer and deter-
mine the cause of recurrent disease process.
Dissection was done using a hysteroscope and other
instruments, and the hysteroscopy control was found toFigure 19 Ultrasonograms of ovaries. (A) Polycystic ovarian syndrome
(PCOS) - enlarged to 55 mm in length with small fluid inclusions.
(B) Hyperstimulated ovary: BRG artefact in follicles.
Figure 20 Polyp relapse. The personalized image of the guided
intervention was considered as the polyp was located close to the
thinning of the uterine wall (arrow).
Figure 21 Uterine cavity after hysteroresection. Sonogram of
unfavorable outcome.
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Among 38 (11.9%) patients, 28 (8.8%) were detected to
have endometrial tissue angles in the uterine tube, and
3.0% of the patients had their endometrium localized in
an isthmus area. Regenerated endometrium is marked by
single pink islands surrounded by scar tissue. All patients
underwent repeat resection of the endometrium. The
presence of proliferative endometrial tissue was confirmed
morphologically.
In our opinion, the cause of EH relapse was insufficient
electrodestruction on specific uterine anatomy. In 22.6%
of patients with AEH and comorbidities (large uterine
fibroids, ovarian cystadenoma), hystero/oophorectomies
were performed.Ultrasound for prediction treatment outcome
In all patients, hysteroresection was successful with no
early complication diagnosed. In 241 patients (75.7%),
US showed normalization of the endometrial structure
and smooth margins of the myometrium. In 76 patients
(23.8%), fibrotic lesions and rough margins of the myo-
metrium were revealed. Endometrial pathology recurrence
after 6 month was revealed in seven patients (2.2%) and
malignancy in nine patients (2.8%). In 19 patients (5.9%),
no US data were found, while clinical symptoms (e.g.,
uterine bleeding) called for intervention. False negative US
results were noted in six patients (2.8%) (Figure 21).Figure 22 Arteriovenous malformation in the anterior
myometrium wall. Hysteroscopy was performed 7 months ago. (A) In
a three-dimensional ultrasound angiography on the anterior
myometrium wall, the tortuous vascular plexus is determined with
interconnected arteries and veins. (B) The blood outflow from the
plexus artery to the vein in the endometrium with spectral arterial flow
(speed up to 4 cm/s) changed by venous flow (up to 1 cm/s) while
transducer was kept in fixed position.Traumatic injuries of the myometrium
In two patients, after 6 months, arteriovenous malforma-
tion (AVM) was revealed. AVM can occur after uterine
curettage or surgery. After a traumatic injury, pseudo-
aneurisms can occur as acquired arteriovenous malforma-
tion, arteriovenous fistula, and direct rupture of blood
vessels (Figure 22).
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optimization of patient-specific operating technique
The causes of disease process recurrence, according to
our study, were a number of factors, namely the lack
of resection and electrodestruction in corners of the
uterus, due to anatomical features (deep corners, the
presence fibromatous nodes, distorting the angle region of
the uterus), and the lack of degradation of the mouths
of the fallopian tube ball electrode and the neck-loop-
peresheechnogo uterine segment electrode. The analysis
of this work has allowed us to identify the risk of recur-
rence of EH on the survey stage and, in the future, to
make adjustments to the operational technique of hys-
teroscopic endometrial ablation.
According to expert recommendations from World
EPMA Congress 2011 in Bonn, it recommended to imple-
ment the concept of model-guided medicine (CARS [1]).
We apply a three-dimensional modeling based on
ultrasound data segmentation and conjoin the models
[62] with those created from different source data of visual
information (CT, MRI, and post-operative photogram-
metry) in a single three-dimensional environment for
planning intervention under the ultrasound guidance in
real time. The three-dimensional modeling becomes a
base of initiation for the model-guided interventions
on female genitals [62].
Sonosurgery
Sonosurgery [63] is a collection of minimally invasive
surgical techniques performed with continuous ultra-
sound imaging and the use of endoscopic tools. It is a
surgical discipline which requires the compliance of
aseptic and medical art conditions and should be per-
formed in the operating unit by experienced personnel.
By medical art, we understand mastery in surgical tech-
niques and ability to perform ultrasound examination by
a physician. However, the simplicity and minimal tissue
trauma in sonosurgical procedures will lead them to be
done in an operating room, similar to procedures in
interventional ultrasonography. Sonosurgical techniques are
performed just like conventional surgery and orthopedics,
but the use of ultrasound equipment can reduce the
operating duration and reduce invasive procedures to
affected tissues.
Discussion
Considering anti-proliferative properties of progesterone
in relation to endometrium, such levels should probably
be regarded as a phase of exhaustion of compensatory
processes, which we believe is the subclinical stage of
transformation of atypical hyperplasia to the endometrial
carcinoma. A slight decrease in estrogen receptor in the
transformation of carcinoma can be explained by the
disappearance of the biological need for the externalsupport of proliferative activity in case of malignancy due
to damage in the genetic apparatus and run their own sys-
tem of uncontrolled cell growth in the endometrium.
These data confirmed the results of the determination of
the proliferative activity of the proliferative marker Ki-67;
it was determined to have a significant increase of 40%
to 50% in the epithelium of the glands while no changes
in the stroma were revealed, as compared to glandular
hyperplasia.
Thus, our analysis of the ratio of receptor in tissue
and endometrial stroma and observation of patients
during personalized treatment allowed us to conclude
as follows:
1. In glandular EH, the concentration of estradiol
receptors in epithelial cells was 75.6% and 30.9% in
the stroma, whereas the rate in the control group was
43.3% and 29.6%, respectively, indicating the sharp
increase (1.8 times) of estrogen receptors in the
endometrium. Analysis of the distribution of receptors
for progesterone showed them having a slight increase
in the endometrium and in the stroma (1.3 times).
2. Distribution of receptor systems in endometrial
polyps characterized by a significant increase in the
number of estradiol receptors in the stroma which
was significantly higher than that in the control
group was 48.2% and 29.6%, respectively (1.7 times).
The content of progesterone receptors in the stroma
was 58.1% and was 55.9% in the endometrial
epithelium in the control group; the content of
progesterone receptors in the stroma was 48.5% and
was 52.4% in the endometrial epithelium.
3. Receptor-negative feature of patients with atypical
endometrial hyperplasia has a significant difference
in the content of progesterone receptors in the
endometrial stroma (81.8%). The content of estradiol
receptors in patients with atypical hyperplasia was
significantly different from that of the control group,
namely estradiol receptors in epithelial cells with
atypical hyperplasia amounted to 65.2%; in the
stroma, 42.6% (in the control, 43.3% and 29.6%
respectively). This receptor combination, we believe,
is the prognostic criteria for determining the
subsequent treatment strategy as the method of
screening for uterine cancer pathology.
4. On the basis of immunohistochemical studies, with
a certain level of receptors for estrogen,
progesterone, and proliferative marker Ki-67, it is an
undoubted fact that the carcinogenesis of endometrial
tumors plays an important role not only on the
hormonal status (hormone levels in the blood), but
also on the so-called receptor imbalance directly in
the endometrium. From the morphological point of
view of the sharp variations in the receptor status
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factor for the development of mutations in the genetic
apparatus and thus tumor development.
5. In relation to further management of patients with
different types of receptor status, we believe that
increasing the percentage of patients having a
decrease in both receptors for progesterone and
estrogen causes endometrial hyperplasia. In fact,
inefficient use of hormone therapy in these patients
underscores the need not only for histological and
hormonal studies but also for complements of the
diagnostic algorithm for determining relationships in
the endometrial receptor system that will allow
pathogenetic therapy. Thus, each individual
pathological pattern of the definition of receptors
and their relationship further defines personalized
pathogenetic tactics, tailored to the person.
6. Ultrasound has sensitivity, specificity, positive and
negative predictive values, and accuracy which were
96%, 85%, 82%, 94%, and 84%, respectively, for early
detection of endometrial hyperplasia and prediction
outcome of a minimally invasive treatment program.
SEG had a sensitivity and specificity of 91% and
83%, respectively, for polyp diagnosis.
7. The study of hormone receptor status in patients
with EH allows to clearly define the treatment policy
and to avoid relapse, optimizing treatment and
observation of such patients.
8. Pharmacotherapy combined with minimally invasive
surgery enabled to treat patients with EH and
significantly reduced radical interventions and time
of treatment.
9. Performing conservative interventions and
personalized pharmacotherapy with subsequent use
of GnRH agonists and progestin on the second stage
is an effective treatment of recurrent EH, which
enabled significantly to reduce the number of radical
interventions and time of treatment.
Consolidation of the PPPM concept
Thus, our analysis of the ratio of receptors in the tissue
and endometrial stroma in observed patients allowed us
to conclude as follows.
Personalized medical approach
Each individual pathological pattern of the definition
of receptors and their relationship combined with US
biomarkers defines further personalized tactics. Three-
dimensional model-guided approach is necessary to per-
form case-specific intervention.
Predictive medical approach
These receptor combination patterns are predictive cri-
teria for determining the subsequent treatment strategyas the method of screening for uterine cancer pathology.
The sharp variations in the endometrium receptor status
can be interpreted as a risk factor for development of
genetic mutations and carcinogenesis.
Preventive medical approach
Our results may lead to the initiation of programs to
prevent endometrial cancer and improve the quality of
life. It is recommended to promote programs for the
introduction of ambulatory ‘office’ of hysteroscopic opera-
tions that will raise the operative outpatient gynecological
care to a new level of efficiency and safety.
Study limitation
Quantitative shear-wave sonoelastography and contrast-
enhanced US were not applied in this study. Particularly,
genetic and cellular mechanisms were out of assessment.
The study was non-randomized and non-blinded. The
confounders as collateral pathologies were present and
not profoundly studied.
Future outlooks and expert recommendations
We suggest further studies to include virus status, im-
mune response, gene damage, and actions of promising
substances as nanomaterials (e.g., nanoceria, nanogold)
for complex impact on female health and collateral
pathologies, and to initiate comparative studies to estab-
lish science-based treatment algorithms and updated
screening programs. After approval, they should develop
safe and effective personalized treatments.
Collateral pathologies related to the studies
Metabolic disturbances in obesity causes a number of
diseases, namely cardiovascular diseases, and a number
of tumor sites of lung cancer, breast cancer, uterine can-
cer, and ovarian cancer; in women, there is a violation
of ovarian menstrual cycle called dyslipidemia. Obesity
reduces life expectancy by 3–5 years, and sometimes, in
severe forms, for 15 years [1,2]. The incidence of endo-
metrial cancer is related to increasing age and, with
39% of cases, is attributed to obesity [64]. The recent
data, regarding women's differential responses to life-
style changes, support another branch of research with
gender nutrition emphasis within predictive, preventive,
and personalized medicine [65].
Illustrated were extensive interrelations among viral
action, cellular oxidative stress, gene damage, multiple
immune pathways and proteomic changes in cancer re-
lated to diabetes mellitus, and many chronic disorder
developments [66]. Many of the chronic diseases are
also related to virus infection (human papillomavirus
(HPV), herpesvirus), followed by gene damage and im-
mune mechanisms involvement [66,67]. HPV infection
is attributed to 80% of all human cancers and was
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breast cancer [66,68]. It was described as a novel im-
proved multimodal diagnostic approach for breast can-
cer risk assessment, which utilizes a combination of
conventional, analytical methodologies for the creation of
pathology-specific biomarker patterns [2,68]. Many endo-
crine, neurologic, autoimmunity, osteoporotic, and neuro-
degenerative diseases [69] are strongly related to the
hormonal status in women.
Expanding the immunologic study
The study is promising to signal pathways imbalance
of pro- anti-inflammatory cytokines, toll-like receptors
in carcinogenesis, and cancer relapse in virus-induced
malignancies. Considering the ability of group factors,
e.g., probiotics, which can promote effective immune
response and initiate an effective immune defence,
probiotic/immunobiotic application might be promis-
ing while integrating the personalized approach.
Biotherapy
The study of different molecular pathways and the cor-
relation of immunohistochemical findings with histo-
logic grade and clinical stage could help in predicting
biologic behavior and planning treatment in patients who
are diagnosed as having these tumors [16]. The funda-
mental studies on endometrial stem/progenitor cells may
provide new insights into the pathophysiology of various
gynecological disorders associated with abnormal endo-
metrial proliferation, including endometrial cancer, endo-
metrial hyperplasia, endometriosis, and adenomyosis [31].
Genetic studies
Discovery of somatically mutated cells in human tissues
has been less frequent than would be predicted by
in vitro mutational rates [21,67].
Nanotechnologies
Nanoparticles of cerium dioxide and gold [70,71] were
reported against oxidative damage, working as anti-ageing
agent. Treatment with nanoceria results in the increase in
the number of oocytes in follicles at metaphases I and II,
increase in the number of living granulosa cells, and de-
crease in the number of necrotic and apoptotic cells [70].
In combination with anti-cancer theranostic application,
it is a promising direction to develop in PPP gynecology
and reproductive medicine.
Mathematical modeling approach
Most processes found in medicine are non-linear, chaotic,
and have a high level of complexity; creating a reliable
mathematical model and use of information technol-
ogy at all stages of the treatment process from
the expression of the pathological processes to theimplementation of therapeutic interventions associated
with patient and physician perception of these phenomena,
and making decisions in the absence of input parame-
ters for the creation of self-controlled systems based on
forecasts of future medical errors are important tasks
[72]. Previously, we reported [73] the approach solving
combinatorial (correctable) problems of selection op-
tions of negative prognostic indicators for interventional
radiology/surgery mistakes to ensure a high level of pa-
tient safety as well as study-level skills and minimal train-
ing required for training programs for interventional
medicine by applying the stochastic method of branches
and boundaries. We suggest that this study would have a
follow-up to assess the multi-parameter data by novel
mathematical model according to which the medical
process is recognized as a complex system like the
‘black box’ [74]. This process (EH progression) is
described by some of the primary indicators (US and
immunohistochemical biomarkers). Thus, primary indi-
cators and output rate are stochastic in nature and
are presented as statistical information. The ‘best’ math-
ematical model of the medical process is studied using a
special algorithm for processing statistical data [2]. We
would recommend the application of one minimal model
to solve tasks as simple as possible.
Fractal geometry is a promising opportunity, especially
the application of fractal analysis in complex systems of
visual diagnostics including radiology and histology data
in order to expand its diagnostic capabilities by increas-
ing the information content for intelligent decision
modeling to reduce subjectivity in the perception and
interpretation [75]. This approach was successfully ap-
plied for hepatic oncology [76].
Education for preventive measures
Educational programs and individual preventive facilities
are the important task for the PPPM concept in women's
health. Dissemination of information is necessary in order
to popularize screening programs and patient participa-
tion approaches against risk factors including obesity, fat
diet, diabetes, menstrual cycle disorders, alertness in never
having been pregnant, receiving hormonal therapy, endo-
crine pathology, cancer prehistory, and family history. The
material for dissemination and lecturing should be stan-
dardized (well translated, to be easily understood) in order
to facilitate the work. Support of preventive educational
activity with long-term commitment of private and public
funding programs is required.
Potential economical impacts
The cost of new gynecological cancers in developing
countries in 2009 totalled to US$1.087 billion compared
to the US$11.913 billion spent in developed countries
[77]; in 2009, cancer costs in the European Union (EU)
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uteri, it was €4.554 billion. The preventive campaigns for
organizational diagnostic tests/programs with focus on
prediction and prevention are available at low costs
(ultrasound, most valid biomarkers) and should valuably
benefit the economy.
Obesity as a condition associated to endometrial path-
ology and uterine cancer accounts for the burden related
to the treatment of these preventable diseases (about
€59 billion a year in EU; US$71.1 billion in the USA).
The combined medical costs attributable to obesity and
overweight are projected to double every decade and will
account for 16%–18% of the total US healthcare expend-
iture by 2030 [78]. Thus, considering integrative medical
approach within the PPPM paradigm directed to women's
health should lead to significant indirect economic benefits.
Promoting programs for the introduction of personal-
ized outpatient gynecological care as the patient-centerd
medical home (PCMH) model based on prediction and
prevention is expected to be more cost effective than
treatment on advanced diseases in large centers.
With the concluding points, we can formulate the
following proposals (expert recommendations):
1. For the EU, an international women's health
project including the study of integrative diagnosis
and treatment of endometrial pathology in regards
to preserving the reproductive function should be
created. There should be a sufficient evidence
study to determine relationships in endometrial
receptor system, genetics, immune pathways to
complement the diagnostic algorithm that will
allow the development of novel treatments and
model-guided approach.
2. For Ukraine, it is recommended to promote
programs for the introduction of personalized
outpatient (office) gynecological care as the
patient-centered medical home (PCMH) model for
healthcare delivery with a high level of efficiency
and patient safety; it is also recommended that
there should be project participation in partnership
with the EU to follow up experimental and clinical
trials and to involve related institutions and centers
to the study.
Conclusions
The study of hormone receptor status combining with
US/sonoelastography data in patients with endometrial
hyperplasia allows for the clear definition of the treat-
ment policy and reduction of relapse. Transvaginal son-
ography in complex application with sonoelastography is
a highly diagnostic screening test for endometrial path-
ology. Performing hysteroresectoscopy and the subse-
quent use of GnRH agonists (Diferelin) and a progestin(endometrin) in the second stage is an effective treatment
of recurrent EH and significantly reduces radical interven-
tions and time of treatment. Pre-operative ultrasound/
radiology data analysis allows the following: to simulate
the upcoming surgery, to set the anatomical features
of the pathologic process, to prevent intra-operative
complications, and to identify areas of risk for the de-
velopment of recurrence.
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